AI Insight
Researchers at Baylor College of Medicine discovered that triple-negative breast cancer cells with both TP53 mutations and loss of one DNA ligase I (LIG1) gene copy develop resistance to platinum-based chemotherapy. The team identified the molecular mechanisms underlying this resistance and successfully used combinations of existing drugs to exploit a therapeutic vulnerability in these cells, reducing tumor growth in animal models. The findings suggest LIG1 status could serve as a biomarker to stratify patients in clinical trials.
Why it matters
This research provides a potential strategy to overcome chemotherapy resistance in a subset of triple-negative breast cancer patients, one of the most aggressive and difficult-to-treat forms of breast cancer. The identification of LIG1 as a stratification marker could help personalize treatment approaches and improve outcomes by matching patients to therapies most likely to be effective for their specific tumor genetics.
Understand the Science
Loss of one copy of the DNA ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage. The team identified underlying molecular mechanisms of platinum resistance that they neutralized with combinations of available drugs to reduce tumor growth in animal models. This work also highlights LIG1 status as a patient stratification factor for ongoing and future clinical trials. The study appeared in Molecular Cancer Therapeutics.
Source: LIG1 loss exposes a therapeutic vulnerability in triple-negative breast cancer